Perindopril: In congestive heart failure

Drugs

Volumn 62, Issue 9, 2002, Pages 1367-1377

  Simpson, Dene ^a   Noble, Stuart ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; ENALAPRIL; LISINOPRIL; PERINDOPRIL;

BLOOD PRESSURE REGULATION; CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG TOLERABILITY; ENZYME INHIBITION; HEART FUNCTION; HEMODYNAMIC MONITORING; HUMAN; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0036073934     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262090-00013     Document Type: Review

References (49)

1. Perindopril: A review of its pharmacological properties and therapeutic use in cardiovascular disorders
2. Perindopril: An updated review of its use in hypertension
3. Perindopril: A review of use in cardiovascular disease
4. New perspectives on heart failure due to myocardial ischaemia
5. HFSA guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction-pharmacological approaches
6. Consensus recommendations for the management of chronic heart failure
7. Current research approaches to the treatment of heart failure
8. The treatment of heart failure
9. Guidelines for the diagnosis and treatment of chronic heart failure
10. Angiotensin converting enzyme (ACE) inhibitors and heart failure: The consequences of underprescribing
11. Class effects of angiotensin-converting enzyme inhibitors
12. ABC of heart failure. Management: Diuretics, ACE inhibitors, and nitrates
13. Practical aspects of hormone suppression in patients with systolic heart failure
14. Neurohormonal mechanisms for heart failure: A central role for the renin-angiotensin system
15. Systemic and regional hemodynamic effects of perindopril in congestive heart failure
16. Acute and long-term efficacy of perindopril in severe chronic congestive heart failure
17. Further evidence that chronic perindopril treatment maintains neurohormonal suppression but does not lower blood pressure in chronic cardiac failure
18. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease
19. Importance of endothelial function in chronic heart failure
20. Endothelial dysfunction: From physiology to therapy
21. The renin-angiotensin system in left ventricular remodelling
22. Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure
23. Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: A review of clinical investigations
24. Effects of angiotensin II antagonists in comparison to ACE inhibitors in patients with heart failure due to systolic left ventricular dysfunction
25. Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure
26. First-dose response to angiotensin-converting enzyme inhibition in congestive cardiac failure: A Malaysian experience
27. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: A placebo controlled study
28. Blood pressure response to the first 36 hours of heart failure therapy with perindopril versus captopril
29. Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure
30. Acceptability of perindopril in mild-to-moderate chronic congestive heart failure: Results of a long-term open study in 320 patients
31. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure
32. Value of perindopril in the treatment of chronic congestive heart failure: Multicenter double-blind placebo-controlled study
33. Comparative haemodynamic responses to the first dose of short- and long-acting ACE inhibitors in patients with congestive heart failure
34. First-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: A comparison of enalapril and perindopril
35. Blood pressure reduction after the first dose of captopril and perindopril
36. Angiotensin-converting enzyme inhibitors in heart failure: Blood pressure changes after the first dose
37. Peripheral artery structure and endothelial function in heart failure: Effect of ACE inhibition
38. Vascular and myocardial protective effects of converting enzyme inhibition in experimental heart failure
39. Prevention of endothelial dysfunction in small and large arteries in a model of chronic heart failure. Effect of angiotensin converting enzyme inhibition
40. Effect of long-term angiotensin-converting enzyme inhibition on vascular function in patients with chronic congestive heart failure
41. Angiotensin-converting enzyme inhibitor therapy improves respiratory muscle strength in patients with heart failure
42. Pharmacokinetic-pharmacodynamic model for perindoprilat regional baemodynamic effects in healthy volunteers and in congestive heart failure patients
43. Pharmacokinetics of perindopril in high-risk populations
44. Blood pressure response to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure
45. A comparative study of the first dose hypotensive effects of captopril and perindopril in patients with heart failure
46. Perindopril in the treatment of congestive heart failure in patients with impaired renal function
47. Angiotensin converting enzyme inhibitor prescribing patterns in patients with heart failure
48. Perindopril for elderly people with chronic heart failure: The PEP-CHF study